Software will
treat the world

WELT closes the gaps between patients and clinicians, and between patients and medicines.
Built on DrugOS™, our digital precision therapy platform,
we deliver prescription digital therapeutics and develop medication-linked treatment technologies.

Explore our technology Our products
For clinicians: prescribing guide →
Korea’s firstIntegrated innovative device review1,200+Eligible prescribing hospitals
130Intellectual property assets101 registered · 29 pending or filed
7SCIE publications2MFDS-authorized DTxCE · ISOInternational certifications

Eligible prescribing hospitals: as of August 2026 · IP assets: valid rights as of July 2026.

Two gaps in care

Treatment and care continue
beyond the consultation

02 · The patient–medication gap
AI-generated scene of a person reviewing medication information at home

Medication use and symptoms
need follow-up after prescribing

Missed doses, treatment interruptions, symptom changes and adverse reactions need attention between visits.

Digital combination drugs · In development

Software support,
from medication use to symptom logs.

Dr.SAM and medication-specific features are being combined for guidance and patient support.

Digital combination drug concept with Dr.SAM software and a medication blister pack
  1. Medication guidanceGuidance during treatment
  2. Symptom logRecords of medication use and symptoms
  3. Progress reviewInformation for clinical follow-up
Combination-drug development
Digital precision therapy platform

DrugOS™,
the foundation for new treatments

Dr.SAM and condition-specific treatment Skills share one development and operating platform.

Technology and use cases
A shared treatment foundationDrugOS™

Dr.SAM + Treatment Skills

SleepQ®SerenQ®Digital combination drugs
54%Shorter follow-on pipeline development timeSleepQ® → SerenQ®
Our treatments

Treatment programs by product

All products
Insomnia · Prescription DTx

SleepQ®

Six weeks of cognitive behavioral therapy

SleepQ sleep health questionnaire screen
SleepQ product screen
Explore treatment program↗
Eating disorders · Prescription DTx

SerenQ®

Eight sessions of cognitive behavioral therapy

SerenQ post-meal reflection screen
SerenQ product screen
Explore treatment program↗
Science, at the core

Possibility,
supported by evidence

Clinical studies, publications, regulatory authorization
and quality systems support every step.

Explore the evidence
SleepQ® · SHAM-CONTROLLED RCT+8.28%p

Between-group improvement in sleep efficiency

JMIR 2025 p = 0.042

Six-week program · Final analysis n=54 · Read paper ↗

Treatment pipeline

A validated start
A broader horizon

Full pipeline
Development overview

Prescription digital therapeutics

Development and commercialization of condition-specific treatment software

4 programs
Product · indication
ConceptDevelopmentClinical trialAuthorizationCommercial
Korea

SleepQ®

Commercial · Nationwide prescribing

Chronic insomnia

MFDS authorization · Insurance listing
Commercial · Nationwide prescribing
Current stage · Commercial5 / 5
  1. Concept
  2. Development
  3. Clinical trial
  4. Authorization
  5. Commercial
Korea

SerenQ®

MFDS authorized

Eating disorders

NET certification
MFDS authorized
Current stage · Authorization4 / 5
  1. Concept
  2. Development
  3. Clinical trial
  4. Authorization
  5. Commercial
Germany

SleepQ® · Germany

Patient follow-up complete; analysis underway

Chronic insomnia

Charité WELT-REST · Preparing for DiGA
Patient follow-up complete; analysis underway
Current stage · Clinical trial3 / 5
  1. Concept
  2. Development
  3. Clinical trial
  4. Authorization
  5. Commercial
Korea

Migraine DTx

Technology development

Migraine

Acquired IP and DrugOS™
Technology development
Current stage · Development2 / 5
  1. Concept
  2. Development
  3. Clinical trial
  4. Authorization
  5. Commercial

Swipe horizontally to explore development stages.

Development overview

Digital combination drugs

Medication-specific treatment and patient-support development

5 programs
Product · indication
Discussion / PoC prepPoCClinical developmentAuthorizationCommercial
Korea

WELT-IP

PoC ongoing

Idiopathic pulmonary fibrosis

Joint development with Ildong
PoC ongoing
Current stage · PoC2 / 5
  1. Discussion / PoC prep
  2. PoC
  3. Clinical development
  4. Authorization
  5. Commercial
Korea

WELT-MN

PoC ongoing

Migraine

PoC ongoing
Current stage · PoC2 / 5
  1. Discussion / PoC prep
  2. PoC
  3. Clinical development
  4. Authorization
  5. Commercial
International

WELT-UA

Urology

Current stage · PoC2 / 5
  1. Discussion / PoC prep
  2. PoC
  3. Clinical development
  4. Authorization
  5. Commercial
Korea

WELT-IS

PoC preparation

Insomnia · Sleep-medication support

Handok · Medication-linked sleep support
PoC preparation
Current stage · Discussion / PoC prep1 / 5
  1. Discussion / PoC prep
  2. PoC
  3. Clinical development
  4. Authorization
  5. Commercial
United States

WELT-MN

Collaboration discussions

Migraine

Discussions on medication-linked development
Collaboration discussions
Current stage · Discussion / PoC prep1 / 5
  1. Discussion / PoC prep
  2. PoC
  3. Clinical development
  4. Authorization
  5. Commercial

Swipe horizontally to explore development stages.

Connected for better care

Building connections for care

한독
일동제약
삼성전자
세브란스서울대병원
Charité Berlin
Our ecosystem
Inside WELT

What’s next at WELT

All news
Money Today

WELT marks its tenth anniversary with plans to expand into AI digital combination drugs

Read more ↗
Ildong press release

WELT and Ildong establish a partnership for digital combination drugs

Read more ↗
Edaily

WELT and Handok expand the SleepQ AI treatment platform

Read more ↗
Build what comes next

Help build the next treatment

Careers at WELT